COPD

A recent study examined the nutritional status and dietary intake among outpatients with chronic obstructive pulmonary disease (COPD) and its possible associations with quality of life.

Researchers investigating the associations between ground-level ozone and fine particulate pollution and emergency department (ED) visits for chronic obstructive pulmonary disease, asthma, and respiratory infections found that as levels rose, more patients land in the ED with breathing problems.

Researchers said they found a previously unreported pathogenic entity that links chronic inflammation and tissue destruction in the lungs of patients with chronic obstructive pulmonary disease (COPD).

When to begin maintenance therapy for patients with chronic obstructive pulmonary disease (COPD) with either a single drug, or a combination of long-acting bronchodilators, is not always clear. A new study looking at whether baseline symptomatic status influences response to treatment suggests that patients with more severe dyspnea benefit more from a combination of tiotropium/olodaterol than tiotropium alone.

Chronic obstructive pulmonary disease is one of the world’s top drivers of chronic disease burdens, the chief executive officer of ResMed told the JP Morgan Healthcare Conference, as he explained the company’s strategy to help meet unmet needs using digital connectivity and data analytics.

A recent study looking at the impact of recent exacerbations of chronic obstructive pulmonary disease (COPD) on hospitalized patients who also have coronary artery disease (CAD) found that COPD was was independently associated with additional risks of complications after percutaneous coronary intervention.

Hospitalized patients with chronic obstructive pulmonary disease (COPD) who tested positive for the flu and were unvaccinated had worse death rates and more severe illness than those who were vaccinated, according to a recent study.

Long-term nicotine replacement therapy (LT-NRT) provides 1 way for smokers with chronic obstructive pulmonary disease (COPD) to try to quit, but does not result in greater rates of cessation or harm reduction, according to a recently published study.

Current guidelines for chronic obstructive pulmonary disease (COPD) call for using antibiotics in the emergency department (ED) when presented with acute exacerbations of COPD (AECOPD). A recent study sought to determine the rate at which patients with AECOPD are treated with antibiotics and also looked at the proportions of antibiotic classes prescribed, trends of antibiotic treatment, and identified independent predictors of antibiotic therapy.

Increased severity of chronic obstructive pulmonary disease (COPD) was associated with an increased risk of mortality and hospitalization in patients with heart failure, according to a recent study published in JAMA Open.

Patients hospitalized with exacerbations of chronic obstructive pulmonary disease (COPD) had worse impairments of cognition compared to those hospitalized without the disease, according to a recent study.

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and patients can differ markedly in their rate of lung function decline and frequency of exacerbations. A recent study sought to determine what proportion of between-individual variability in symptoms can be explained by lung function versus all other observable characteristics.

A recent report, published by the Annals of the American Thoracic Society, assessed trends in chronic obstructive pulmonary disease (COPD) hospitalizations and in-hospital deaths in the United States and found that the number of in-hospital deaths for COPD has decreased; however, women account for a higher proportion of the hospitalizations and in-hospital deaths.

A recent study aimed to identify the characteristics of patients who demonstrate the greatest exacerbation risk reduction with roflumilast, finding that the medication is most successful in patients with prior hospitalization, greater exacerbation frequency, and higher baseline blood eosinophil count.

Propeller Health, a digital health company that makes sensors to track patient use of respiratory inhalers used for chronic obstructive pulmonary disease (COPD) and asthma, is being snapped up by ResMed, which makes connected devices for respiratory care.

Researchers investigated the association between chronic obstructive pulmonary disease (COPD) phenotypes and the prognosis of different histological subtypes of lung cancer and found that COPD, especially emphysema-predominant phenotype, was an independent prognostic risk factor for squamous carcinoma only.

By meeting challenges in caring for patients with chronic obstructive pulmonary dieases head-on, primary care doctors have an opportunity to reduce the potential for unnecessary or sub-optimal care while improving patient outcomes.

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, and for COPD Awareness Month this November, The American Journal of Managed Care® conducted a Q&A with Jamie Sullivan, MPH, vice president of public policy and outcomes for The COPD Foundation, as well as Chief Medical Officer Byron M. Thomashow, MD. The COPD Foundation is a not-for-profit organization that works to improve the lives of patients with COPD.

Recent research indicates that there are age-associated gender differences seen in the disease burden of chronic obstructive pulmonary disorder (COPD), with younger women more severely affected.

An investigation into the effects of a self-management intervention (SMI) called “Better Living with COPD” found that the intervention had a significant positive short-term effect for patients with chronic obstructive pulmonary disease.

It is already well established that patients with COPD have exacerbations during winter as well as during heat waves in the summer months, and researchers in Germany sought to see which patient groups might be potentially more vulnerable to the effects of climate change in order to see who might need targeted care.

Retraction and republication: The JAMA article referenced in this story was retracted and republished on October 8, 2019. Please refer to the updated findings here.

The FDA approved revefenacin (Yupelri), the first once-a-day nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD).

Inhaled corticosteroids, used for preventing acute exacerbation of chronic obstructive pulmonary disease (COPD), often lead to increased high blood eosinophil count, while low blood eosinophil count is often associated with pneumonia risk—however, the prognostic role of blood eosinophil count has not yet been explored. In a recent study, researchers found that the severity of emphysema was independently linked with low blood eosinophil count and the longer survival period was associated with increased blood eosinophil count.

Researchers recently studied the adverse outcomes of symptomatic and asymptomatic nonobstructed individuals and those with mild chronic obstructive pulmonary disease (COPD) longitudinally, and found that the presence of respiratory symptoms in nonobstructed individuals was a predictor of mortality, lung function decline, and exacerbations.

A new report on the prevalence of chronic obstructive pulmonary disease (COPD) shows that there is wide variability across and within states, with West Virginia carrying the highest burden of morbidity and mortality.

Researchers reviewed the most updated concepts of the pulmonary vascular changes in chronic obstructive pulmonary disease (COPD) and concluded that certain subgroups of COPD patients with pulmonary vascular phenotypes may profit from targeted pulmonary arterial hypertension therapy.

Researchers looked to evaluate predictors of mortality in patients with COPD after 9 years.

The first trial to examine the impact of a self-management behavior-modification program combined with bronchodilator therapy and exercise training on exercise capacity and physical activity in patients with chronic obstructive pulmonary disease (COPD) showed positive results, according to a recently published study.

Oral theophylline has been used as a bronchodilator to treat chronic obstructive pulmonary disease (COPD) for decades, but it has fallen out of favor due to the side effects that come with the higher doses that are required to achieve any beneficial effect. A recent study sought to determine if adding low-dose theophylline to inhaled corticosteroids for COPD would reduce the number of exacerbations.